CLN2 Test Meeting Room

CLN2 Test Meeting Room
Wednesday 14th April 16:00 - 17:00 GMT

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Are you a healthcare professional?

The information provided on this website is intended for use by healthcare professionals practicing in the Europe. The dissemination of this information may be subject to different medical and regulatory requirements across Europe.​

I confirm that I am a healthcare professional practicing in Europe I am a member of the public

All the content about BRINEURA® (cerliponase alfa) currently available on CLN2 Meetings platform has been approved and is consistent with the latest and most updated version of EU SmPC.​

CLN2 Meetings’ content is periodically reviewed by BioMarin and may be subject to changes to assure compliance with EMEA general regulations around on promotion of prescription medicines.

You can always find out the most updated version of Brineura’s abbreviated prescribing information (API) under the menu option "API" at the top bar navigation.​


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.